Rifaldin 300 mg cápsulas

DRUG2 trials

Sponsors

Bellvitge University Hospital, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL, Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Conditions

Enterococcus faecalis infectious endocarditisLatent tuberculosis infection in patients with end-stage kidney disease.

Phase 4

Comparison of treatment completion rates with three short-course rifamycin-based regimens (three months of daily isoniazid plus rifampicin [3HR], three months of once-weekly isoniazid plus rifapentine [3HP], and four months of daily rifampicin [4R]) for treatment of latent tuberculosis infection in patients with end-stage kidney disease: A randomised controlled clinical trial (RIFAKiD-TB Trial)

Active, not recruitingCTIS2023-506432-32-00

Bellvitge University Hospital, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELLLatent tuberculosis infection in patients with end-stage kidney disease.

Start: 2024-04-11Target: 225Updated: 2025-01-20

Efficay and safety of ampicillin and ceftriaxone continuous infusion versus standard therapy for the treatment of Enterococcus faecalis infective endocarditis (DOβLEI Study)

RecruitingCTIS2024-511719-40-00

Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De SevillaEnterococcus faecalis infectious endocarditis

Start: 2024-10-09Target: 284Updated: 2025-07-16